Allogene Therapeutics (ALLO) Accounts Payables (2018 - 2026)

Allogene Therapeutics has disclosed Accounts Payables across 9 years of filings, most recently posting $4.9 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.9 million, down 2.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (down 2.47% YoY), and the FY2025 annual result was $4.3 million, down 20.84% from the prior year.
• Accounts Payables came in at $4.9 million for Q1 2026 at Allogene Therapeutics, up from $4.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $14.7 million in Q1 2023 to a low of $3.7 million in Q3 2025.
• The 5-year median for Accounts Payables is $5.9 million (2023), against an average of $7.8 million.
• Across the five-year window, Accounts Payables surged 68.67% in 2023 and plunged 62.5% in 2025, its largest moves.
• Allogene Therapeutics' Accounts Payables stood at $13.9 million in 2022, then tumbled by 57.54% to $5.9 million in 2023, then slipped by 8.53% to $5.4 million in 2024, then decreased by 20.84% to $4.3 million in 2025, then advanced by 15.53% to $4.9 million in 2026.
• The last three Accounts Payables figures came in at $4.9 million (Q1 2026), $4.3 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.